Global Markets
Roche (ROP SW) receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA
StockNow breaking-news AI analysis
FDA approved companion diagnostic testing for ZIIHERA in HER2-positive metastatic GEA, where clinical regimens showed extended 26.4-month median overall survival and significantly expanded the drug's addressable market.
What do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.